Trials / Completed
CompletedNCT01101334
Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer
Phase 2 Study of CS-7017 and Erlotinib in Subjects With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 and open-label (subject will know the treatment he or she is receiving) study. The subject will receive either Erlotinib alone or Erlotinib + CS-7017 in this study. The study will determine what effect adding CS-7017 to Erlotinib has on safety and length of survival in subjects with advanced non-small cell lung cancer who failed the first treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CS-7017 | CS-7017, Two 0.25mg Tablets administered twice daily |
| DRUG | erlotinib | Erlotinib; One 150mg tablet administered once daily |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2013-04-01
- Completion
- 2013-04-01
- First posted
- 2010-04-09
- Last updated
- 2020-06-16
- Results posted
- 2020-06-16
Locations
17 sites across 4 countries: United States, Germany, India, South Korea
Source: ClinicalTrials.gov record NCT01101334. Inclusion in this directory is not an endorsement.